Trial Profile

A Phase 1b, Open-label, Multicenter, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of AG-181 in Subjects With Phenylketonuria

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AG 181 (Primary)
Indications Phenylketonuria
Focus Adverse reactions
Sponsors Agios Pharmaceuticals

Most Recent Events

30 Jul 2026 According to an Agios Pharmaceuticals media release, the company dosed the first patient in the Phase 1b trial evaluating the safety and tolerability of AG-181 in adults with PKU. Data from this trial are expected in the second half of 2026
24 Apr 2026 Status changed from not yet recruiting to recruiting.
12 Jan 2026 According to an Agios Pharmaceuticals media release, data from this trial will be presented at J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com